Mottolese M, Bigotti G, Coli A, Vitucci C, Natali P G
Department of Pathology, Regina Elena Cancer Institute, Rome, Italy.
Am J Clin Pathol. 1991 Aug;96(2):233-7. doi: 10.1093/ajcp/96.2.233.
Immunohistochemical (IHC) assays using the monoclonal antibodies (MoAbs) B72.3 and B6.2, recognizing two distinct and independently expressed breast tumor-associated antigens (BTAAs), recently have been shown to significantly improve the accuracy of cytodiagnosis of breast nodules by fine-needle aspiration (FNA). To evaluate whether the same method may be useful diagnostically in distinguishing gynecomastia from breast cancer in men, a retrospective avidin-biotin immunoperoxidase assay study was performed on 50 cases of gynecomastia and 30 cases of breast carcinoma in men, using a panel of five MoAbs known to recognize different BTAAs. The results of this study demonstrated that MoAbs B1.1, HMFG2, and MBr1 displayed a strong reactivity with gynecomastia and carcinoma, but MoAbs B72.3 and B6.2 separated benign and malignant lesions in a high percentage of cases. When used in combination, the latter two reagents reacted with 96% of the carcinomas that were analyzed but labeled only 67% of gynecomastia cases. Thus, the conjoint use of these two reagents may enhance the use of FNA biopsy as a valuable tool in the presurgical diagnosis of breast nodules in men.
使用单克隆抗体（MoAbs）B72.3和B6.2进行的免疫组织化学（IHC）检测，可识别两种不同且独立表达的乳腺肿瘤相关抗原（BTAAs），最近已显示出能显著提高细针穿刺（FNA）对乳腺结节的细胞诊断准确性。为评估同一方法在鉴别男性乳腺增生与乳腺癌方面是否具有诊断价值，对50例男性乳腺增生和30例男性乳腺癌病例进行了一项回顾性抗生物素蛋白-生物素免疫过氧化物酶检测研究，使用了一组已知可识别不同BTAAs的五种单克隆抗体。该研究结果表明，单克隆抗体B1.1、HMFG2和MBr1对乳腺增生和癌均表现出强反应性，但单克隆抗体B72.3和B6.2在高比例病例中可区分良性和恶性病变。当联合使用时，后两种试剂与96%的所分析癌发生反应，但仅标记了67%的乳腺增生病例。因此，联合使用这两种试剂可能会增强FNA活检作为男性乳腺结节术前诊断有价值工具的作用。
